Marinomed Biotech (Austria) Price Prediction
| MARI Stock | 18.90 0.10 0.53% |
Momentum 33
Sell Stretched
Oversold | Overbought |
Using Marinomed Biotech hype-based prediction, you can estimate the value of Marinomed Biotech AG from the perspective of Marinomed Biotech response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Marinomed Biotech to buy its stock at a price that has no basis in reality. In that case, they are not buying Marinomed because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Marinomed Biotech after-hype prediction price | EUR 18.9 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Marinomed |
Marinomed Biotech After-Hype Price Density Analysis
As far as predicting the price of Marinomed Biotech at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Marinomed Biotech or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Marinomed Biotech, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Marinomed Biotech Estimiated After-Hype Price Volatility
In the context of predicting Marinomed Biotech's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Marinomed Biotech's historical news coverage. Marinomed Biotech's after-hype downside and upside margins for the prediction period are 17.76 and 20.04, respectively. We have considered Marinomed Biotech's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Marinomed Biotech is very steady at this time. Analysis and calculation of next after-hype price of Marinomed Biotech is based on 3 months time horizon.
Marinomed Biotech Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Marinomed Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Marinomed Biotech backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Marinomed Biotech, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.13 | 1.14 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
18.90 | 18.90 | 0.00 |
|
Marinomed Biotech Hype Timeline
Marinomed Biotech is now traded for 18.90on Vienna Exchange of Austria. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Marinomed is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at -0.13%. %. The volatility of related hype on Marinomed Biotech is about 0.0%, with the expected price after the next announcement by competition of 18.90. About 38.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 4.0. Marinomed Biotech had not issued any dividends in recent years. Assuming the 90 days trading horizon the next forecasted press release will be uncertain. Check out Marinomed Biotech Basic Forecasting Models to cross-verify your projections.Marinomed Biotech Related Hype Analysis
Having access to credible news sources related to Marinomed Biotech's direct competition is more important than ever and may enhance your ability to predict Marinomed Biotech's future price movements. Getting to know how Marinomed Biotech's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Marinomed Biotech may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| AMAG | AMAG Austria Metall | 0.00 | 0 per month | 0.59 | 0.02 | 2.52 | (1.23) | 5.40 | |
| SBMO | SBM Offshore NV | 0.00 | 0 per month | 0.51 | 0.30 | 3.13 | (1.57) | 9.94 | |
| UQA | UNIQA Insurance Group | 0.00 | 0 per month | 1.08 | 0.18 | 2.33 | (1.85) | 6.55 | |
| WPB | Wiener Privatbank SE | 0.00 | 0 per month | 0.89 | 0.12 | 2.97 | (2.45) | 6.80 | |
| VIG | Vienna Insurance Group | 0.00 | 0 per month | 1.09 | 0.23 | 5.80 | (2.34) | 10.36 | |
| RBI | Raiffeisen Bank International | 0.00 | 0 per month | 1.53 | 0.16 | 4.19 | (3.06) | 8.74 | |
| UMG | Universal Music Group | 0.00 | 0 per month | 0.00 | (0.18) | 1.76 | (2.31) | 8.42 |
Marinomed Biotech Additional Predictive Modules
Most predictive techniques to examine Marinomed price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Marinomed using various technical indicators. When you analyze Marinomed charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Marinomed Biotech Predictive Indicators
The successful prediction of Marinomed Biotech stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Marinomed Biotech AG, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Marinomed Biotech based on analysis of Marinomed Biotech hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Marinomed Biotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Marinomed Biotech's related companies.
Currently Active Assets on Macroaxis
Complementary Tools for Marinomed Stock analysis
When running Marinomed Biotech's price analysis, check to measure Marinomed Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinomed Biotech is operating at the current time. Most of Marinomed Biotech's value examination focuses on studying past and present price action to predict the probability of Marinomed Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinomed Biotech's price. Additionally, you may evaluate how the addition of Marinomed Biotech to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |